ANNX

Annexon, Inc. (ANNX) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Annexon, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for complement-mediated neuroinflammatory diseases. The company has no approved products and has not generated any revenue from product sales. Its primary focus is advancing two late-stage programs: tanruprubart for Guillain-Barré Syndrome (GBS) and vonaprument for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Key Financial Metrics

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by $10.2 million (19%) compared to Q1 2025, primarily driven by a $12.4 million reduction in operating expenses.
• Operating Expense Reduction: Total operating expenses declined 20% to $46.1 million.
  • R&D Expenses: Decreased 26% to $35.8 million. This was largely due to a $11.2 million decrease in contract manufacturing costs associated with completed activities for the tanruprubart European MAA filing and vonaprument technology transfer. This was partially offset by a $3.4 million increase in clinical services for the vonaprument Phase 3 ARCHER II trial and the tanruprubart FORWARD study.
  • G&A Expenses: Increased 11% to $10.3 million, driven by a $1.2 million rise in consulting and professional services for corporate affairs.
• Interest Income: Interest and other income, net, decreased 37% to $1.9 million due to lower average cash and investment balances.
• Capital Raise: The company raised approximately $32.7 million in net proceeds during the quarter through the sale of common stock under its 2024 At-The-Market (ATM) program.

Guidance, Outlook, and Risks

• Liquidity Outlook: As of March 31, 2026, the company held $225.0 million in cash, cash equivalents, and short-term investments. Management projects these resources will fund operations into the second half of 2027. The company expects to continue incurring losses for the foreseeable future.
• Regulatory Milestones:
  • Tanruprubart (GBS): A Marketing Authorization Application (MAA) was filed with the European Medicines Agency (EMA) in January 2026 and is under review. The company plans to engage with the FDA in 2026 following data from the FORWARD study to support a Biologics License Application (BLA).
  • Vonaprument (GA): Enrollment for the Phase 3 ARCHER II trial was completed in July 2025. Topline data is expected in the fourth quarter of 2026.
  • ANX1502: An oral small molecule candidate is in a proof-of-concept study for cold agglutinin disease, with an update expected in 2026.
• Capital Markets: In March 2026, the company entered a new $150 million ATM program with TD Cowen. Subsequent to the quarter end, it sold shares for approximately $8.1 million in net proceeds. The 2024 ATM program was terminated in May 2026.
• Risks: Key risks include the failure to obtain regulatory approval for product candidates, the inability to raise additional capital on acceptable terms, reliance on third-party manufacturers, and the potential for clinical trial delays or negative results.

Investor Verification Checklist

• Verify the status of the tanruprubart MAA review with the EMA and any feedback received from the FDA regarding the generalizability of data from non-Western populations.
• Confirm the timeline for topline data release for the vonaprument ARCHER II Phase 3 trial (expected Q4 2026).
• Monitor the company's cash burn rate and the utilization of the new $150 million ATM program to ensure the runway extends into late 2027 as projected.
• Review the contract manufacturing arrangements and supply chain stability for both tanruprubart and vonaprument as they approach potential commercialization.
• Assess the impact of the 2024 ATM program termination and the execution of the new 2026 ATM program on share dilution.